A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

This randomised multicentre phase II study was conducted to investigate the activity and safety of two oral fluoropyrimidines, capecitabine or S-1, in elderly patients with advanced gastric cancer (AGC). Elderly (⩾65 years) chemo-naive patients with AGC were randomly assigned to receive capecitabine...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2008-08, Vol.99 (4), p.584-590
Hauptverfasser:	Lee, J-L, Kang, Y-K, Kang, H J, Lee, K-H, Zang, D Y, Ryoo, B-Y, Kim, J G, Park, S R, Kang, W K, Shin, D B, Ryu, M-H, Chang, H M, Kim, T-W, Baek, J H, Min, Y J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - secondary Adenocarcinoma - surgery Aged Aged, 80 and over Antimetabolites, Antineoplastic - therapeutic use Biomedical and Life Sciences Biomedicine Bone Neoplasms - drug therapy Bone Neoplasms - secondary Bone Neoplasms - surgery Cancer Research Capecitabine Clinical Study Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Drug Combinations Drug Resistance Epidemiology Feasibility Studies Female Fluorouracil - analogs & derivatives Fluorouracil - therapeutic use Humans Liver Neoplasms - drug therapy Liver Neoplasms - secondary Liver Neoplasms - surgery Lymphatic Metastasis Male Molecular Medicine Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Oncology Oxonic Acid - therapeutic use Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - secondary Peritoneal Neoplasms - surgery Prognosis Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Stomach Neoplasms - surgery Survival Rate Tegafur - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!